“We look forward to the strategic cooperation with Selecxine in the field of innovative drug development. In recent years, the Korean biopharmaceutical industry has grown rapidly. Among the innovative biotech companies in Korea, Selecxine has extensive experience in innovative therapeutic drugs,” said Dr. Brian Min, CEO of GenScript BDBU. “This cooperation once again demonstrates our superior process development capabilities. In the future, we want to enable more innovative companies like Selecxine to accelerate the development of innovative therapies and the approval of new drugs. » View original content to download multimedia:www.prnewswire.com/news-releases/genscript-and-genopis-enter-strategic-partnership-agreement-for-manufacture-service of-gmp-plasmids-300987347.html SEOUL, South Korea, Dec. 26, 2019 /PRNewswire/ — Am Dec. 23, 2019, in Seoul, South Korea, the CDMO segment of global biotechnology leader GenScript announced that it has signed a strategic cooperation agreement with Selecxine Inc., a Korean biotechnology company dedicated to new therapeutic drugs for immunoncology. The parties have entered into a partnership for the development of innovative antibody drugs. According to the agreement, GenScript will be responsible for preclinical pharmaceutical research and IND submission in the Selecxine project.
This project is based on cytokine antibody complexes. Compared to conventional monoclonal antibodies and protein drugs, this project offers new insight into the development of new drugs. Through the strategic collaboration with GenScript ProBio, Initium Therapeutics plans to use GenScript ProBio`s Berkeley Lights Beacon platform to expand its antibody-active ingredient pipeline. The largest GenScript plasmid and virus factory in China has been commissioned NANJING, China, Jan. Jan. 16, 2020 /PRNewswire/ — On January 14, 2020, a global biotechnology company GenScript announced that it has signed a strategic partnership agreement for the manufacture of GMP plasmids with Genopis, Inc., a company specializing in plasmid DNA-based technology and specializing in the development of orders and products from the Employment and Employment Policy Commission (CDMO). With the conclusion of this strategic partnership agreement, GenScript and Genopis enter into a revenue participation agreement for the promotion, sale and production of GMP plasmids worldwide. “We are delighted to be working with Genopis. Last month, our plasmid and virus factory was commissioned in Zhenjiang. This is an important step on the road to the industrialization of gene and cell therapy products developed by GenScript, and we have been the Chinese leaders in this field. Dr. Brian Min, Managing Director of GenScript`s Bioologics Development Business Unit, said: “Genopis is an accredited U.S. cGMP manufacturer with the ability to produce GMP plasmid, and this partnership will continue to grow our services worldwide.
We will use the strengths of both companies. Genopis` experience and ability to efficiently carry out the production of GMP, both for clinical trials and for commercial purposes, are the main assets of this cooperation, which will ultimately accelerate the development of new and new drugs and therapies. Dr. Jun-Young Lee, CEO of Selecxine, said at the signing ceremony: “I am so excited to work with CDMO GenScript to develop our lead candidate SLC-3010. In recent years, we have seen GenScript`s capability as a global CDMO through successful performance in several SLC-3010 subprojects. I believe that the new, closer partnership agreement, which covers a wide range of new drug development processes, from stable cell line development to the production of GMP-3010, will lead us to clinical trials.